Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A US appeals court has overturned a lower court ruling that several generic manufacturers did not infringe Pfizer's patent for stabilized formulations of gabapentin, the active ingredient in Neurontin.
Subscribe to our email newsletter
The Court of Appeals for the Federal Circuit ruled that the New Jersey federal district court should not have granted summary judgment to the generic manufacturers, and that a full trial should be held on Pfizer's allegations of patent infringement.
Pfizer said the ruling will allow the company to seek a judgment of infringement and, if successful, pursue full compensation for the damages it suffered due to the 2004 at-risk launch of generic versions of epilepsy drug Neurontin.